ALCAM and neoplasm: Antigen-specific targeting of CX-2009 was further confirmed by immunofluorescent staining of tumor, liver, and kidney tissue by analyzing the level and pattern of CD166 expression as well as the level and pattern of CX-2009 tissue binding 72 h after administration to H292 tumor-bearing mice.